Peptide vs Drug vs Biologic

Updated August 2026 · Patriot Labs Research Team · ~28 min read

The short answer

Whether a peptide is a drug or a biologic depends on two things: how long it is, and what it is claimed to do. In the United States the length boundary is exact — a defined-sequence amino acid polymer of 40 residues or fewer is a peptide and is regulated as a drug; one greater than 40 residues is a protein, and a protein is a biological product regulated under a different statute entirely.^[5][18]

That is the whole answer. It is worth knowing that 40 is not a chemical fact — nothing happens to a chain between its fortieth and forty-first residue. The line is an administrative choice, made in a rulemaking.

The second half matters more in practice. A substance becomes a drug in US law largely because of what it is claimed to do, not because of what it is. The same molecule can be a drug, a cosmetic ingredient, a food component or none of the above, depending on the intent evidenced by whoever sells it. This is the intended use doctrine.

The last row is where research-grade material sits, and it deserves saying plainly: material sold for in-vitro laboratory use is outside the approval framework, not blessed by it. Patriot Labs material is research chemical stock. It is not approved, cleared, licensed or evaluated by FDA, and any vendor using regulatory vocabulary to imply their catalogue has been reviewed is telling a story.

What chemistry actually says

Peptides and proteins are the same kind of object: chains of amino acids joined by amide bonds. The beginner guide to peptides covers that chemistry; what matters here is where the naming conventions fall and why they are only conventions.

Textbooks disagree. One widely used reference calls a chain of roughly 2 to 50 amino acids a peptide, applies oligopeptide to chains of about 10 to 20, and uses polypeptide above roughly 20.^[40] Reviews of therapeutic peptides work in mass instead — roughly 500 to 5,000 Da — and note that synthesis beyond about 50 residues stays difficult.^[38] None of these agree, and none claims to be more than a working convention.

They disagree because there is nothing there to agree about. The transition is gradual and it is about structure, not count. Every chain has a primary structure — its sequence. Secondary structure, the helices and sheets held by backbone hydrogen bonds, becomes possible as chains lengthen; short chains in solution are mostly disordered. Tertiary structure, a three-dimensional fold with a hydrophobic core, is what makes a protein a protein functionally — and it is where the counter-examples live: the designed miniprotein Trp-cage folds cooperatively at just 20 residues, half the regulatory threshold.^[39] Quaternary structure is the association of chains, and insulin is the textbook case: chains of 21 and 30 residues held by disulfide bonds, 51 in total but no contiguous run longer than 30.^[41] Hold that detail.

If size is a poor divider, what tracks something real? Characterisation difficulty. FDA's plain-language framing is that most drugs are chemically synthesised with a known structure, whereas “most biologics are complex mixtures that are not easily identified or characterized.”^[30] ICH Q6B, the international quality guideline for biotechnology products, covers proteins and polypeptides from cell culture, explicitly excludes synthetic peptides, and notes that where physicochemical information “may be extensive but unable to confirm the higher-order structure,” a biological assay may be needed instead.^[37] That is the real dividing line: the point at which chemistry alone stops proving what is in the vial. It is fuzzy, molecule-specific and expensive to litigate, so the law drew a number instead.

What “drug” means in US law

The definition sits in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 321(g)(1). It is four clauses joined by “and,” which function in practice as alternatives — meeting any one is enough:^[1]

(A) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component of any article specified in clause (A), (B), or (C).

Read clause (C) again. Articles intended to affect the structure or any function of the body. No disease required, no prescription, no injection — and almost every claim ever made about a bioactive peptide is a structure-or-function claim. Clause (A) is the quiet one: compendial recognition alone makes an article a drug. The word doing the heaviest lifting is intended.

Intended use: the doctrine doing the work

US drug law is not primarily a law about molecules. It is a law about purposes. The regulation at 21 CFR 201.128 defines “intended uses” as the objective intent of the persons legally responsible for the labelling of an article, shown by their expressions and statements, by the design or composition of the article, by the circumstances of distribution, and by labelling claims, advertising or other statements.^[6]

FDA amended that regulation in a final rule published 2 August 2021, effective 1 September 2021, precisely to make the evidentiary scope explicit.^[11] Its position is that intended use may be established from any relevant source, and that limiting the analysis to explicit claims would let a seller escape the framework “by simply omitting explicit promotional claims or by making claims that are not true.”^[11]

Two consequences follow. Chemistry does not determine category on its own — a molecule is not inherently a drug, which is why one compound can occupy different categories depending on who sells it. And a disclaimer is evidence, not a shield: one input among many, and where inputs conflict it loses. The research-use-only section is where that bites.

What “biological product” means

Biologics are not governed by the FD&C Act's approval provisions but by section 351 of the Public Health Service Act, codified at 42 U.S.C. § 262 — a licensing statute rather than an approval statute. Section 351(i)(1) defines the term:^[2]

a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.

It is a list — historically, of things that came from living systems and could not be fully characterised. The word protein is the catch-all that swept in the modern biotechnology industry, and it determines where peptides fall. Section 351(a) then requires a licence before a biological product enters interstate commerce.^[2] The statute does not define “protein.” A regulation does.

The 40-amino-acid line

21 CFR 600.3(h)(6) reads, in full:^[5]

A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. When two or more amino acid chains in an amino acid polymer are associated with each other in a manner that occurs in nature, the size of the amino acid polymer for purposes of this paragraph (h)(6) will be based on the total number of amino acids in those chains, and will not be limited to the number of amino acids in a contiguous sequence.

Every phrase is load-bearing. “Specific, defined sequence” means the residue order must be determinate; FDA explained in 2018 that proteins have a sequence “generally provided by a corresponding DNA or RNA sequence.”^[8] That excludes heterogeneous mixtures of fragments — a hydrolysate has no defined sequence, however large its pieces (hold that for the collagen section). “Greater than 40 amino acids in size” puts 41 and up in the protein category; the synthetic peptide guidance states the converse: “FDA considers any alpha amino acid polymer composed of 40 or fewer amino acids to be a peptide, not a protein.”^[18]

The second sentence is the insulin sentence. Without it, insulin's longest chain is 30 residues and insulin is a peptide. With it, the naturally associated A and B chains count together at 51, and insulin is a protein.^[41] One sentence of regulatory text decides the status of the most widely used biological medicine in the world.

How that line got drawn

The number has a paper trail, and reading it is the fastest way to see that the boundary is administrative.

December 2018 — the proposed rule. FDA published a proposed rule at 83 FR 63817 under docket FDA-2018-N-2732, proposing the definition that now stands.^[8] Its stated reasoning was that a 40-residue threshold was “more appropriate based on the scientific literature and alignment with current regulatory practice,” and that polymers greater than 40 amino acids “may often assume several of the structural and functional characteristics that are generally associated with proteins.”^[8] Note the hedges — may often assume, several of, generally associated. Not a claim that something changes at 41; a claim that a threshold has to go somewhere and 40 is defensible.

The polypeptide carve-out. The statute then excluded from “protein” any chemically synthesized polypeptide, so the proposal defined that too: an alpha amino acid polymer made entirely by chemical synthesis and greater than 40 but less than 100 amino acids in size.^[8] That would have produced three zones, with manufacturing route changing a molecule's legal category.

February 2020 — the final rule. Congress intervened first: the Further Consolidated Appropriations Act, 2020 struck the parenthetical. FDA's final rule at 85 FR 10057, published 21 February 2020 and effective 23 March 2020, codified the protein definition but abandoned the polypeptide one, stating it was “not finalizing our interpretation of ‘chemically synthesized polypeptide’ because of the removal ... from the category of ‘protein.’”^[9]

The result: one line, at 40, and manufacturing route is irrelevant to it. A 60-residue chain built entirely by solid-phase synthesis is a biological product; a 30-residue chain expressed in engineered E. coli is not. The guide to how peptides are made covers both routes; neither maps onto the legal category.

What changes when a molecule crosses 40

Crossing the line changes almost everything about a product's commercial life, none of it because of chemistry.

The exclusivity row is commercially decisive. A peptide drug faces generic competition once its five-year new chemical entity exclusivity and patents lapse, and generics substitute at the counter on a therapeutic equivalence rating. A protein gets twelve years, and its follow-ons are biosimilars, not automatically substitutable unless separately designated interchangeable.^[2][19] Seven extra years, determined by residue count.

NDA, ANDA, 505(b)(2), BLA, 351(k)

Five application types cover almost everything, and the names get used loosely enough to be worth pinning down.

Two things to carry forward. The ANDA route exists only for drugs — there is no generic biologic in US law, only a biosimilar. And 505(b)(2) is the hybrid: a full application leaning on someone else's findings.

March 2020: the day insulin became a biologic

If one episode proves these categories are legal statuses rather than molecular properties, it is this one.

For decades insulin, human growth hormone and other protein products were approved as drugs, under NDAs, because they predated the modern biologics framework. Section 7002(e) of the Biologics Price Competition and Innovation Act of 2009 fixed that: an approved application for a biological product held under the FD&C Act would be deemed to be a licence under section 351 of the PHS Act on 23 March 2020.^[15]

On that date roughly 140 approved NDAs became BLAs.^[16] No reformulation, no new data, no change to a single vial — and an original 505(b)(1) application still pending at 11:59 pm that night received a complete response, because the pathway it was filed under had ceased to exist.^[15]

That last row is the point of the table. Glucagon and insulin are both pancreatic hormones, both made recombinantly, both injected. One is a biological product and one is a drug, and the only legally decisive difference is 29 residues against 51.

The compounding consequence shows how far the category reaches. FDA's notice to compounders explained that from 23 March 2020 the transitioning products “will not be eligible for the exemptions for compounded drugs under sections 503A and 503B,” naming chorionic gonadotropin, hyaluronidase, follicle-stimulating hormone and menotropins as the bulk substances affected.^[17] A change in statutory category eliminated a class of compounded preparation overnight.

Where peptides sit: the synthetic-peptide policy

Because peptides sit on the drug side of the line, they get the drug toolkit — including generics. FDA has an explicit policy for the commonest case: a chemically synthesised peptide copying one originally made by recombinant DNA technology.

The guidance, announced at 86 FR 27446 on 20 May 2021 under docket FDA-2017-D-5767,^[10] states that it “provides recommendations for evaluating whether an ANDA submission is appropriate for a synthetic peptide that references any of the following five previously approved peptide drug products of rDNA origin: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide.”^[18]

All five are 40 residues or fewer, and all five were originally produced biologically. FDA's position is that modern analytical chemistry can establish that a synthetic version has the same active ingredient, so an abbreviated application is appropriate. The guidance sets conditions: peptide-related impurities common to both must be at equal or lower levels in the generic, novel impurities are held to a threshold expressed as a fraction of the drug substance, and any new impurity must be justified against immunogenicity risk.^[18] It is the cleanest demonstration that manufacturing route does not determine category.

The modern GLP-1 receptor agonists sit in the same territory. Tirzepatide was approved under NDA 215866 on 13 May 2022 — an NDA, not a BLA, because at 39 residues it is a peptide.^[20] Compounds still in development, such as retatrutide, are in the same length class, while a four-residue compound like SS-31 sits at the other extreme. The category spans two orders of magnitude and still lands entirely on one side of the line. For what identity and purity data actually prove about a batch, see the guide on reading a peptide certificate of analysis.

How a molecule gets sorted into a category

Put all of that together and sorting is a sequence, not a lookup. This is the order the questions actually get asked.

1. Is there an intended use that touches a regulated category at all? Intent is established from statements, labelling, advertising, design, composition and circumstances of distribution.^[6][11] If nothing points at a disease claim, a structure-or-function claim, a cosmetic purpose or a dietary purpose, no category is triggered — and no approval framework applies. That is where research chemicals sit.
2. Is it intended for diagnosis, cure, mitigation, treatment or prevention of disease, or to affect structure or function? If yes, it is a drug under § 201(g)(1)(B) or (C), or a biological product.^[1]
3. Is it an alpha amino acid polymer with a specific, defined sequence? A mixture of hydrolysed fragments is not. A single defined molecule is.^[5]
4. Count the residues. Where chains associate in a manner that occurs in nature, count the total across chains, not the longest contiguous run.^[5]
5. Forty or fewer? It is a peptide, not a protein — a drug travelling the § 505 pathway: NDA, 505(b)(2) or ANDA.^[18][3]
6. More than forty? It is a protein, therefore a biological product under § 351(i), requiring a licence — 351(a) for the originator, 351(k) for a biosimilar.^[2]
7. Check the non-drug alternatives only if step 2 failed. A cosmetic purpose keeps it a cosmetic; a dietary purpose with a qualifying ingredient and no exclusion keeps it a supplement. A structure-or-function claim sends it back to step 2.^[29]
8. Run the separate axes independently. Controlled-substance scheduling, import rules and sport anti-doping status are decided by different bodies under different authority.

Steps 1 and 2 come before any chemistry. That ordering is the thing most explanations get backwards.

“Research use only”: what it is, and what it is not

This is the section most readers came for, so it gets the plainest treatment on the page.

“Research use only” is not an FDA status. There is no application for it, no review of it, no register of products holding it. FDA does not grant it, withhold it or evaluate anything about a product carrying it. It is a statement of intended use, made by a seller.

The phrase has one genuine regulatory home, and its narrowness is instructive. 21 CFR 809.10(c)(2)(i) governs the labelling of in-vitro diagnostic products: for a product in the laboratory research phase that is not represented as an effective diagnostic, the regulation requires the prominent statement “For Research Use Only. Not for use in diagnostic procedures.”^[7] That is a labelling requirement for diagnostic reagents, not a general exemption for chemicals, and it says nothing about safety, quality or approval.

It is not an approval, not a clearance, not a licence,^[2] not an exemption from the intended use analysis but one piece of evidence within it,^[11] and not a statement about purity or identity, which are shown by data.

FDA has said this directly in enforcement correspondence. A warning letter dated 17 June 2026 reads: “Despite statements on your product labeling marketing your products for, ‘RESEARCH USE ONLY’ and ‘not for human consumption,’ evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use.”^[21] An earlier letter, 26 February 2025, said the same of a site carrying “research use only” and “lab purposes only” disclaimers.^[22] In both, the determinative evidence was the seller's own marketing copy.

The lesson is not that a disclaimer is meaningless. It is that the disclaimer describes intent, other conduct also describes intent, and the whole record is read together. FDA's public position on unapproved GLP-1 products puts it bluntly, referring to companies that “falsely labeled” products “for research purposes” or “not for human consumption” while selling them directly to consumers with dosing instructions.^[27]

The honest summary: research-grade material occupies the last row of the table at the top of this page. It is outside the approval framework and has not been evaluated by anyone at FDA — the absence of an endorsement, not a hidden one. The buying guide covers what actually is checkable about a supplier.

Compounding, 503A and the bulks lists

Compounding is where peptides most often collide with the regulatory system, and the area moved substantially between 2023 and 2026.

Sections 503A and 503B exempt certain compounded preparations from some drug requirements — 503A for a licensed pharmacist or physician, 503B for registered outsourcing facilities. Both restrict which bulk drug substances may be used. Under 503A a substance qualifies if it complies with an applicable USP or NF monograph, or is a component of an FDA-approved drug product where no monograph exists, or appears on FDA's 503A bulks list. Most research peptides satisfy none of the three. FDA received more nominations than it could evaluate at once, so it published an interim policy sorting them into three categories, which in the January 2025 revision read:^[23]

Several peptides landed in Category 2 over the years, which is why the phrase circulates so widely. As of FDA's page current on 22 April 2026, the 503A Category 2 substances were cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine hydrochloride.^[24] The list is shorter than it has been, because a group of peptide nominations was withdrawn by their nominators.

Coming off Category 2 is not the same as being permitted. FDA scheduled its Pharmacy Compounding Advisory Committee to consider seven peptide substances on 23–24 July 2026 — BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and semax, each in free base and acetate form — and its briefing document proposes that each of the fourteen forms not be included on the 503A bulks list.^[25]

The 503B position is narrower still: the final 503B bulks list contained five entries as of its 21 August 2023 update — diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid. No peptides.^[26] FDA's page on unapproved GLP-1 drugs also states that retatrutide and cagrilintide cannot legally be used in compounding and have not been found safe and effective for any condition.^[27]

Two honest observations. The lists have changed repeatedly, so any statement about them carries a date. And none of it changes the status of laboratory research material, which is not inside the compounding framework at all.

Dietary supplements and the collagen contrast

A common assumption is that if a peptide is not a drug it must be a supplement. It generally cannot be, for two reasons.

The ingredient list. Section 201(ff) defines a dietary supplement as a product intended to supplement the diet that bears or contains a dietary ingredient — a vitamin, a mineral, a herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet, or a concentrate, metabolite, constituent, extract or combination of those.^[1] A vitamin qualifies by name, which is why vitamin B12 is squarely a dietary ingredient. “Amino acid” qualifies too — but a specific synthetic sequence of amino acids is a defined molecule, not an amino acid, and it is not a botanical, a mineral or a traditional dietary substance.

The exclusionary clause. Section 201(ff)(3)(B) removes from the definition any article “approved as a new drug ... certified as an antibiotic ... or licensed as a biologic ... or an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, which was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food.”^[1]

Read the middle of that carefully. It is not limited to approved drugs. An article authorised for investigation as a new drug, where substantial clinical investigations have begun and been made public, is excluded — unless it was already marketed as a food or supplement first. That rule catches a great many bioactive peptides, because the ones people are interested in are precisely the ones that have entered clinical development.

The collagen contrast. Hydrolysed collagen is sold everywhere as “collagen peptides” and is unambiguously a food ingredient, because it is not a defined-sequence molecule: it is a heterogeneous mixture of fragments with a distribution of chain lengths rather than a sequence. It fails the “specific, defined sequence” test in 21 CFR 600.3(h)(6) by construction.^[5]

Even collagen made by fermentation goes down the food route when its use is a food use. FDA's response to GRAS Notice GRN 1171 records no questions on the notifier's conclusion that a collagen polypeptide produced by an engineered E. coli strain is generally recognised as safe in foods.^[28] Recombinant production, food category. The category follows the purpose, not the process.

Cosmetics, and the claim that flips the category

Topical peptides are common in skincare, and cosmetics are the clearest place to watch the intended use doctrine operate, because the same jar can move between categories on one sentence of marketing copy. Section 201(i) defines a cosmetic as articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness or altering the appearance.^[1] Cosmetics need no pre-market approval of the finished product; drugs do. The boundary is commercially enormous, and it is drawn entirely by claims.

FDA explains that classification turns on intended use, established three ways: claims on the label, in advertising and in promotional material; consumer perception, including established reputation; and the presence of ingredients with a well-known therapeutic purpose.^[29] Some products meet both definitions at once — an anti-dandruff shampoo cleanses and treats dandruff — and those “must comply with the requirements for both cosmetics and drugs.”^[29]

The structure-or-function row is where most skincare marketing gets into difficulty: claims about mechanism are structure-function claims. Describing what a molecule does in the skin, rather than how the product looks on it, is the crossing point.

Controlled substances: a separate axis

People frequently collapse “unapproved” and “controlled” into one idea; they are separate systems. The Controlled Substances Act schedules substances by abuse potential, accepted medical use and dependence liability, and DEA maintains the list. Peptide hormones do not appear on it: the DEA alphabetical list of controlled substances, in its 12 August 2026 version, contains synthetic cannabinoids, fentanyl analogues, cathinones, benzodiazepines and anabolic steroids, and no peptide hormones.^[31]

One precisely bounded exception exists, and it is a criminal provision in the FD&C Act rather than a scheduling provision. 21 U.S.C. § 333(e) makes it an offence punishable by up to five years' imprisonment to knowingly distribute or possess with intent to distribute human growth hormone for any use in humans other than treatment of a disease or recognised medical condition authorised by the Secretary and pursuant to a physician's order; the penalty rises to ten years where a person under 18 is involved. It defines human growth hormone as “somatrem, somatropin, or an analogue of either of them.”^[4] That Congress had to legislate specifically for growth hormone shows the general framework does not reach these compounds through scheduling.

WADA: banned in sport is not the same as illegal

The World Anti-Doping Agency publishes an annual Prohibited List applying to athletes bound by the World Anti-Doping Code. The 2026 list came into force on 1 January 2026.^[32]

Two categories matter here. S2 covers peptide hormones, growth factors, related substances and mimetics, prohibited at all times, in and out of competition. S0 covers non-approved substances — described in WADA's athlete guide as experimental or designer drugs — likewise prohibited at all times.^[33] S0 sweeps in most research peptides precisely because they are unapproved. The US Department of Defense's Operation Supplement Safety programme, for instance, records that BPC-157 is listed in class S0 and states plainly that it “is not a dietary ingredient.”^[34]

The honest paragraph: an anti-doping rule is a contractual and sporting rule, not a law. WADA is a private foundation, and its List is incorporated by sports bodies into rules athletes agree to. A substance being on the List says nothing about whether possessing it violates a statute, and its absence says nothing about whether selling it with drug claims is lawful.

The EU draws the line differently

Nothing about the 40-residue rule is inevitable, and the fastest way to see that is a jurisdiction that reached a different answer. The European Union does not define a biological medicinal product by residue count but by the source and characterisation of the active substance: a biological substance is one produced by or extracted from a biological source, whose characterisation requires physico-chemical-biological testing together with knowledge of the production process and its control. A chemically synthesised molecule is not a biological substance under that definition, however long it is.

The EMA guideline on synthetic peptides, EMA/CHMP/CVMP/QWP/367182/2025, adopted December 2025 and applicable from 1 June 2026, states the consequence directly: “The biosimilar regulatory pathway is not possible for chemically synthesised peptides since these fall outside the definition of a biological substance.” It nonetheless advises that the basic principles of demonstrating biosimilarity be considered where such a programme uses a biological medicinal product as its reference.^[35]

The Court of Justice of the European Union addressed the resulting question in Case C-118/24, decided 23 April 2026, concerning a chemically synthesised teriparatide referencing a biological reference product.^[36] That dispute is the European mirror image of FDA's synthetic-peptide ANDA guidance. Both systems reached a workable answer to the same problem by different roads and different criteria — about as clear a demonstration as one could ask for that the US line at 40 is a choice rather than a discovery.

What this framework does not settle

Every section above describes what the categories decide. This one describes what they do not.

Not whether a molecule works. Category is orthogonal to evidence. A compound can be a drug in the statutory sense on the strength of a claim alone, with no supporting data. The definition is triggered by intent, not by proof.

Not safety. Neither “drug” nor “biological product” is a safety verdict; they are procedural routes. The verdict, where one exists, comes from approval of a specific product for a specific labelled use, and does not transfer to other products containing the same molecule.

Not quality. Nothing in the distinction speaks to what is in a particular vial. Identity, purity, counterion and water content are answered by batch data — the subject of the certificate of analysis guide.

And a category label is not a quality signal. “Regulated as a drug” describes a pathway a hypothetical approved product would travel; it says nothing about material that never entered it. Research-grade stock has no approval, no licence, no clearance and no FDA evaluation of any kind, and understanding the framework properly should make that absence more visible, not less.

It also does not stand still. The 40-residue rule is stable; the material around it is not. Compounding lists changed repeatedly between 2023 and 2026, guidance is revised, enforcement priorities shift. Everything here is stated as of the date at the top of the page, and anyone checking a current position should go to the primary sources rather than any secondary summary, this one included. Finally, this guide explains how statutory categories are constructed using the primary texts — it is not legal advice, it does not assess any particular product or activity, and it is no substitute for advice from a qualified attorney.

Frequently asked questions

Is a peptide a drug?

It depends on length and on intended use. Under the Federal Food, Drug, and Cosmetic Act an article becomes a drug when it is intended for the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or any function of the body.^[1] Chemistry alone does not make something a drug; a claim does. Separately, a defined-sequence amino acid polymer of 40 residues or fewer is a peptide rather than a protein, so it travels the drug pathway.^[18]

Are peptides biologics?

Usually not, in the strict US regulatory sense. The Public Health Service Act defines a biological product to include a protein,^[2] and FDA's regulation defines a protein as any alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids in size.^[5] A peptide of 40 residues or fewer therefore falls outside the protein category and is regulated as a drug. Above 40 residues the same molecule would need a biologics license application.

What is the 40 amino acid rule?

It is the boundary in 21 CFR 600.3(h)(6): a protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. Where two or more chains are associated in a manner that occurs in nature, the count is the total across those chains, not the longest contiguous run.^[5] Forty or fewer means peptide and the drug pathway; more than forty means biological product. FDA finalised the number in February 2020.^[9]

Why is insulin a biologic now?

Because of a statutory transition, not because the molecule changed. Human insulin is two chains of 21 and 30 residues, 51 in total, above the line once naturally associated chains are counted together.^[5][41] Section 7002(e) of the Biologics Price Competition and Innovation Act provided that approved applications for biological products held under the FD&C Act would be deemed to be biologics licences on 23 March 2020. Insulins, somatropin, pancrelipase, gonadotropins and hyaluronidase moved that day.^[15][16]

Are peptides FDA approved?

Some peptide molecules are the active ingredient in approved drug products — tirzepatide, for instance, under NDA 215866 in May 2022.^[20] Most research peptides are not. Approval is granted to a specific product, from a specific manufacturer, for a specific labelled use, on the basis of a submitted application. It does not attach to a molecule in the abstract, and it never attaches to material sold outside the approval framework.

What does research use only mean?

It is a statement of intended use, not a regulatory status FDA grants. There is no FDA category called research use only for chemicals. The one place the phrase appears in regulation is the labelling rule for in-vitro diagnostic products in the laboratory research phase, which requires the statement “For Research Use Only. Not for use in diagnostic procedures.”^[7] FDA has said in enforcement letters that such a disclaimer does not override other evidence of intended use.^[21][22]

Can peptides be compounded?

Only a narrow set can. A bulk drug substance qualifies under section 503A if it has a USP or NF monograph, is a component of an FDA-approved drug product, or appears on FDA's 503A bulks list. Most research peptides meet none of the three. FDA sorted nominated substances into interim categories and placed several peptides in Category 2, meaning they may present significant safety risks.^[23][24] Licensed biological products are outside the 503A and 503B exemptions entirely.^[17]

Are peptides legal?

Peptides are almost never controlled substances — DEA's list contains no peptide hormones^[31] — so they are not illegal to possess the way a scheduled drug is; one narrow criminal provision covers human growth hormone specifically.^[4] The legal questions that actually arise are different: whether a product is marketed with drug claims without an approved application, whether it is misbranded, and whether it is eligible for compounding. Sport bodies apply a separate rulebook.^[33]

What is the difference between a peptide, a polypeptide and a protein?

Chemically there is no sharp boundary. All three are chains of amino acids joined by amide bonds, and textbook conventions disagree with each other. One common convention calls a chain of roughly 2 to 50 residues a peptide, applies polypeptide above about 20, and reserves protein for chains long enough to fold into stable higher-order structure.^[40] What changes with length is folding and characterisation difficulty, and both change gradually.^[39] The regulatory line at 40 is a policy choice laid across that gradient.

Does a peptide count as a dietary supplement?

Generally no. The statutory list of dietary ingredients covers vitamins, minerals, herbs, amino acids and dietary substances used to supplement the diet, and a defined-sequence synthetic peptide is none of them. A separate exclusionary clause removes any article approved as a new drug, licensed as a biologic, or authorised for investigation as a new drug with public substantial clinical investigations, unless marketed as a food or supplement first.^[1] Hydrolysed collagen differs: it is a mixture of fragments, not a defined sequence.^[5]

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational, describes statutory and regulatory categories in general terms, and is not legal advice; it does not assess any particular product or activity, and the compounds named in it are discussed only as regulatory examples. Nothing here states or implies that any Patriot Labs product is approved, cleared, licensed or otherwise evaluated by any regulatory authority — research-grade material sits outside that framework entirely. For advice on a specific situation, consult a qualified attorney. More about us is on the about page.

For in-vitro research and laboratory use only. Not for human consumption.